Mohamed G. Elbanan MBBCh, Presenter: Nothing to Disclose

Eslam Wassal Youssef MD, Abstract Co-Author: Nothing to Disclose

Pascal O. Zinn MD, Abstract Co-Author: Nothing to Disclose

Rivka Rachel Colen MD, Abstract Co-Author: Nothing to Disclose

Sp1 plays a critical role in the regulation of multiple genes implicated in tumorigenesis, also it represents potential prognostic markers for glioma progression. Currently used methods to determine the Sp1 expression status of GBM include immunohistochemical analysis and genotyping of the DNA extracted from the brain tumor specimens. Thus, we seek to identify a diffusion and conventional MR imaging signature associated with Sp1 expression tumors that can be considered as a non-invasive predictor of the Sp1 expression status in Glioblastoma patients.

We identified 80 GBM patients from The Cancer Genome Atlas (TCGA) who had genetic expression profiles of Sp1 and neuroimaging available at The Cancer Imaging Archive (TCIA). All morphological image analyses and segmentation were done using slicer 3.6 (slicer.org) and reviewed in consensus by 3 neuroradiologists. Fluid-Attenuated Inversion Recovery (FLAIR) was used for segmentation of the edema and post-contrast T1 weighted imaging (T1WI) for segmentation of enhancement (defined as tumor) and necrosis. The non-enhancing perilesional FLAIR hyperintensity reflected a mixture of edema/tumor infiltration. Diffusion was analyzed in Olea Sphere 2.3 and Conventional FLAIR/post- contrast T1WI was registered to DWI/ADC maps. ADC, FLAIR and T1 Gadolinium enhancement values will be measured using the ROI based method, in the perilesional edema/non enhancing tumor and the enhancing tumor zones, with dividing the perilesional edema/non enhancing tumor into 3 zones each of 1 cm width, 3 ROI measurements will be taken from each zone. Multiple quantitative imaging features were identified and combined to create the imaging biomarker signature predictive of Sp1 expression status status.  

We created a complex imaging biomarker signature using quantitative diffusion and conventional MR imaging features to predict those GBM patients with Sp1 expression status and furthermore that was predictive of patient survival.

GBM tumors with Sp1 expression status hold a specific imaging biomarker signature that can be used as a predictive and prognostic biomarker and non-invasive surrogate for Sp1 expression status.

GBM tumors with Sp1 expression hold a specific diffusion and conventional MR imaging biomarker signature that can be used as a predictive and prognostic biomarker.

Elbanan, M, Youssef, E, Zinn, P, Colen, R, Diffusion and Conventional MR Imaging Genomic Biomarker Signature Predicts Specificity Protein 1 Expression Identification in Glioblastoma Patients.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14045719.html